

CMCN

Canadian Medical Cannabis Trials Network

*Jason Busse
Hance Clarke
Lauren Kelly
James MacKillop*




RFA 4 – New Trial Networks



Network Need

- One in eight Canadian adults endorse use cannabis for medical purposes, but most indications lack high-quality evidence.
- Primary indications are for chronic pain and mental illness.
- The CMCN will address this knowledge gap by supporting high-quality, rigorous trials of medical cannabis products.



Membership

Addiction Psychiatry

Anesthesia

Anesthesia and pain management

Bio-analytical chemistry

Biostatistics

Cell Biology and Anatomy

Family Medicine

Medicinal chemistry

Molecular and cell biology

Molecular biology

Neurology

Oncology

Pain and substance use

Palliative Care

Pediatrics

Pharmacology

Pharmacology and Therapeutics

Psychiatry


Psychology

Research methods

Rheumatology

Sociology

Surgery




RFA 4 – New Trial Networks

ACT Accelerating
AEC Clinical Trials 
Accélérer les
Essais Cliniques


 **CIHR** Canadian Institutes of
IRSC Health Research
Instituts de recherche
en santé du Canada

Structure




Network Engagement

- Early Career Working Group to promote career development opportunities and mentoring relationships.
- RCT Peer Review Working Group to provide substantive and constructive peer-review of grants.
- Patient Experience Advisory Board.
- Collaboration with Six Nations of the Grand River.



Initial RCT

- Cannabidiol (CBD) vs. placebo to reduce persistent pain after TKA.
- 40-patient, parallel, feasibility RCT.
- CIHR-funded.
- A successful pilot will facilitate pursuit of funding for a definitive trial.



Question Period

CMCN: Canadian Medical Cannabis Clinical Trials Network

Dr. Jason Busse

02:00